



Dear PACES participant,

On behalf of the study team, I would like to thank you for enrolling in S0820, also known as PACES: Preventing Adenomas of the Colon with Eflornithine and Sulindac.

With the growing number of cancer survivors in the U.S. today, there has been a renewed interest in reducing the risk of second cancers, or pre-cancerous conditions among cancer survivors. As a result of screening practices, early detection efforts, and modern treatment advances, there are now more than 1 million colorectal cancer survivors living in the U.S. today – and the number is increasing! With the increasing number of colorectal cancer survivors has come increased interest in ways to reduce the risk of new colorectal adenomas (pre-cancerous polyps within the colon) or new colon cancers.

After optimal treatment for colon cancer, survivors have increased risk of new colorectal cancers compared to the risk of the underlying population. The investigators of PACES have designed this study to investigate potential ways to reduce the risk of high-risk adenomas or new colorectal cancers among colon cancer survivors. The active medications used in PACES (eflornithine, sulindac) were shown in a previous study to have substantial effects when used for 3 years (versus placebos) among patients with colorectal adenomas at baseline. However, it is not known if the observed benefits in the prior trial will extend to colon cancer survivors – only through the conduct of PACES will we have that answer.

We believe that despite the advances of the past couple of decades in the prevention and management of colon cancer – more can be done to lower the risk of future cancers, and that this must be accomplished through clinical research. We also believe that the future of preventive medicine involves targeting at-risk groups, and that colon cancer survivors represent a group of individuals that stand to benefit from further risk reduction strategies. This philosophy is endorsed by the PACES study team, SWOG, and the National Cancer Institute who graciously provides support. However, the study is made possible because of you, and the other participants, without which there would be no further clinical research advances. Therefore I extend to you my gratitude, and I look forward to your participation in this important study.

Sincerely,

A handwritten signature in black ink that reads "Jason A Zell". The signature is written in a cursive, flowing style.

Jason A. Zell, D.O., M.P.H.

Principle Investigator, S0820 (PACES)